Industry News

On September 24, 2019, HFA and NHF sent a聽letter聽to Genentech and MedVantx regarding the shipment of incorrect length injection needles to patients who receive Hemlibra through the Genentech Patient Foundation. The Genentech Patient Foundation responded to our inquiries by letter dated September 25, 2019. You can read their response聽here.

HFA and NHF will update the bleeding disorders community as any further information develops.

Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, please consult your physician.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.